Amwill Health Care Ltd, a derma-cosmetic development company, is launching its Initial Public Offering (IPO) to raise capital for expansion and growth. The IPO is scheduled to open on February 5, 2025, and close on February 7, 2025. The company has set a price band of ₹105 to ₹111 per equity share, with a lot size of 1,200 shares, requiring a minimum investment of ₹1,33,200. The shares are expected to be listed on the BSE SME platform on February 12, 2025.

Company Overview

Established in 2017, Amwill Health Care Ltd specializes in developing dermatological, cosmeceutical, and aesthetic products. The company collaborates with contract manufacturers, distributors, and third-party developers, allowing it to focus on product formulation and innovation while outsourcing manufacturing, packaging, and distribution. Operating primarily in Karnataka, Andhra Pradesh, and Telangana, Amwill aims to deepen its market presence before expanding into new regions. The product portfolio includes solutions for skin care, hair care, personal care and hygiene, and lip care.

IPO Details

• Issue Size: The IPO comprises a total of 54,03,600 equity shares, aggregating up to ₹59.98 crore. This includes a fresh issue of 44,03,600 equity shares and an offer for sale of 10,00,000 equity shares by existing shareholders.

  Price Band: ₹105 to ₹111 per equity share of face value ₹10 each.

  Lot Size: Investors can bid for a minimum of 1,200 equity shares and in multiples thereof.

  Key Dates:

  • IPO Opening Date: February 5, 2025
  • IPO Closing Date: February 7, 2025
  • Allotment Date: February 10, 2025
  • Listing Date: February 12, 2025

Financials

Over the past three fiscal years, Amwill Health Care Ltd has demonstrated significant growth:

The company’s revenue and net profit have shown a consistent upward trend, with a notable increase in net profit in FY 2023-24. Additionally, the company has successfully reduced its debt to zero by FY 2023-24, indicating strong financial health.

Strengths

• Focused Product Development: By outsourcing manufacturing and distribution, Amwill concentrates on developing innovative dermatological solutions.
• Strategic Market Presence: The company has established a strong foothold in key southern states of India, providing a solid base for future expansion.
• Diverse Product Portfolio: Catering to various segments within the personal care industry enhances market reach and customer engagement.

Risks

• Dependency on Third Parties: Reliance on external partners for manufacturing and distribution may pose challenges related to quality control and supply chain management.
• Market Competition: The personal care industry is highly competitive, with numerous established players, which could impact market share and profitability.

IPO Anchor Investors Details

As of now, specific details regarding anchor investors for the Amwill Health Care Ltd IPO have not been disclosed. Investors are advised to monitor official communications from the company and regulatory filings for updates.

IPO Promoter Holding

Note: Specific data regarding promoter holdings before and after the IPO is currently unavailable. Investors should refer to the company’s official prospectus for detailed information.

IPO Grey Market Premium (GMP)

As of now, information regarding the Grey Market Premium for Amwill Health Care Ltd’s IPO is not available. Investors should exercise caution and refer to official sources for the most accurate and updated information.

Final Thoughts

Amwill Health Care Ltd’s upcoming IPO presents an opportunity to invest in a growing derma-cosmetic company with a focused business model and strategic market presence. Potential investors should carefully consider the company’s financial performance, strengths, and associated risks. It is advisable to review the official prospectus and consult with financial advisors before making investment decisions.